Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

PD
Measured advantages of remote patient monitoring in automated peritoneal dialysis - Amici G et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Tria - Zickler D et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-off Delivering Expanded Haemodialysis Therapy: Improving Clinical and Economic Outcomes in the Real-World European Medical Journal
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off Dialysis Membrane and Dietary Fiber Effects on Inflammation and Protein-Bound Uremic Toxins: A Systematic Review and Protocol for an Interventional Study.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off Dialyzer versus Eight Hemodiafiltration Dialyzers: Comparison Using a Global Removal Score - Maduell F et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-off Dialyzers in a Large Population of Hemodialysis Patients in Colombia: COREXH Registry
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off Membrane Can Be a New Treatment Tool in Amanita phalloides Poisoning.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium cut-off membranes - closer to the natural kidney removal function
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off Membranes: Incremental or Quantum Leap Innovation in Haemodialysis?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cut-Off versus Low-Flux Dialyzers in Hemodialysis Patients with COVID-19: Clinical Outcomes and Reduction in Interleukin-6
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium Cutoff Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment Weighting
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium cut‑of dialyzer for middle molecular uremic toxins in AKI and chronic dialysis
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.